Arrowstreet Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Arrowstreet Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-79,287	Closed	-$10.5M	–	2136
2025 Q1	$10.5M	Buy	+79,287	New	+$9.88M	0.01%	798
2024 Q3	–	Sell	-3,906	Closed	-$268K	–	1909
2024 Q2	$268K	Buy	+3,906	New	+$271K	﹤0.01%	1415
2023 Q3	–	Sell	-9,671	Closed	-$612K	–	1458
2023 Q2	$612K	Buy	+9,671	New	+$603K	﹤0.01%	1041
2022 Q3	–	Sell	-9,238	Closed	-$527K	–	1489
2022 Q2	$527K	Sell	9,238 -4,663	-34%	-$264K	﹤0.01%	1061
2022 Q1	$851K	Buy	+13,901	New	+$722K	﹤0.01%	964
2020 Q4	–	Sell	-21,919	Closed	-$562K	–	2585
2020 Q3	$562K	Buy	+21,919	New	+$500K	﹤0.01%	1987
2020 Q1	–	Sell	-8,700	Closed	-$298K	–	2168
2019 Q4	$298K	Buy	+8,700	New	+$104K	﹤0.01%	1570
2016 Q4	–	Sell	-17,990	Closed	-$274K	–	2602
2016 Q3	$274K	Buy	+17,990	New	+$727K	﹤0.01%	1365

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Arrowstreet Capital's ITCI Position: Q2 2025 in Review

Arrowstreet Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 79,287 shares — an estimated $10.5M sold.

Arrowstreet Capital first reported a position in ITCI in Q3 2016 and held it in 8 quarters. The position peaked at $10.5M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Arrowstreet Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Arrowstreet Capital sold 79,287 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $10.5M.
Arrowstreet Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 8 quarters.
Arrowstreet Capital's Intra-Cellular Therapies Inc. position peaked at $10.5M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Arrowstreet Capital's 13F filing for Q2 2025, filed 13 Aug 2025.